Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

COPENHAGEN, DENMARK (Reuters) -Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.